<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="ajo13888" xml:lang="en" article-type="other"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Aust N Z J Obstet Gynaecol</journal-id><journal-id journal-id-type="iso-abbrev">Aust N Z J Obstet Gynaecol</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1479-828X</journal-id><journal-id journal-id-type="publisher-id">AJO</journal-id><journal-title-group><journal-title>The Australian &#x00026; New Zealand Journal of Obstetrics &#x00026; Gynaecology</journal-title></journal-title-group><issn pub-type="ppub">0004-8666</issn><issn pub-type="epub">1479-828X</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39333023</article-id><article-id pub-id-type="pmc">PMC12099178</article-id>
<article-id pub-id-type="doi">10.1111/ajo.13888</article-id><article-id pub-id-type="publisher-id">AJO13888</article-id><article-id pub-id-type="other">ANZJOG-2024-0269</article-id><article-categories><subj-group subj-group-type="overline"><subject>Position Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Position Paper</subject></subj-group></article-categories><title-group><article-title>Position statement on the management of pregnancy in sickle cell disease</article-title><alt-title alt-title-type="right-running-head">Pregnancy in SCD</alt-title><alt-title alt-title-type="left-running-head">M. Yue <italic toggle="no">et al.</italic>
</alt-title></title-group><contrib-group><contrib id="ajo13888-cr-0001" contrib-type="author"><name><surname>Yue</surname><given-names>Mimi</given-names></name><xref rid="ajo13888-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ajo13888-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ajo13888-cr-0002" contrib-type="author"><name><surname>Mason</surname><given-names>Kylie</given-names></name><xref rid="ajo13888-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ajo13888-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ajo13888-cr-0003" contrib-type="author"><name><surname>Rowlands</surname><given-names>Shelley</given-names></name><xref rid="ajo13888-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ajo13888-cr-0004" contrib-type="author"><name><surname>Kaplan</surname><given-names>Zane</given-names></name><xref rid="ajo13888-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="ajo13888-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="ajo13888-cr-0005" contrib-type="author"><name><surname>Kennedy</surname><given-names>Debra</given-names></name><xref rid="ajo13888-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="ajo13888-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="ajo13888-cr-0006" contrib-type="author" corresp="yes"><name><surname>Kidson&#x02010;Gerber</surname><given-names>Giselle</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-5834-0890</contrib-id><xref rid="ajo13888-aff-0009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="ajo13888-aff-0010" ref-type="aff">
<sup>10</sup>
</xref><address><email>giselle.kidsongerber@health.nsw.gov.au</email></address></contrib></contrib-group><aff id="ajo13888-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Haematology</named-content>
<institution>Mater Health Service</institution>
<city>Brisbane</city>
<named-content content-type="country-part">Queensland</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">School of Medicine</named-content>
<institution>University of Queensland</institution>
<city>Brisbane</city>
<named-content content-type="country-part">Queensland</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Haematology</named-content>
<institution>Peter MacCallum Cancer Centre and the Royal Melbourne Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Sir Peter MacCallum Department of Oncology</named-content>
<institution>University of Melbourne</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Maternal Fetal Medicine</named-content>
<institution>Royal Women's Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Monash Haematology</named-content>
<institution>Monash Health</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine, School of Clinical Sciences at Monash Health</named-content>
<institution>Monash University</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>Royal Hospital for Women, Randwick Campus</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Schools of Medicine and Women's and Children's Health, Prince of Wales Hospital and Royal Hospital for Women Clinical School</named-content>
<institution>University of NSW</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="ajo13888-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Haematology</named-content>
<institution>NSW Health Pathology, Prince of Wales Hospital and Royal Hospital for Women, Randwick Campus</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<italic toggle="yes">Correspondence:</italic> Dr Giselle Kidson&#x02010;Gerber, Department of Haematology, NSW Health Pathology, Prince of Wales Hospital, Barker St, Randwick, 2031, NSW, Australia. Email: <email>giselle.kidsongerber@health.nsw.gov.au</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><volume>65</volume><issue seq="30">2</issue><issue-id pub-id-type="doi">10.1111/ajo.v65.2</issue-id><fpage>183</fpage><lpage>189</lpage><history>
<date date-type="received"><day>11</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>11</day><month>9</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2025 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">Australian and New Zealand Journal of Obstetrics and Gynaecology</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Royal Australian and New Zealand College of Obstetricians and Gynaecologists.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:AJO-65-183.pdf"/><abstract><p>Sickle cell disease (SCD) is a hereditary haemoglobinopathy which causes multi&#x02010;organ dysfunction. Pregnancies in SCD are high risk with significant maternal and fetal morbidity and mortality, including vaso&#x02010;occlusive crises, thrombosis, anaemia, placental insufficiency, fetal growth restriction, preterm birth and medication effects. High level evidence on this topic is lacking. The Australian Sickle Cell Disease Working Group has reviewed international guidelines on this topic and provide an up&#x02010;to&#x02010;date and structured approach to the pre&#x02010;conception, antenatal, birth and post&#x02010;partum management of these women. Early and comprehensive multidisciplinary care involving experienced clinicians is recommended.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ajo13888-kwd-0001">anaemia</kwd><kwd id="ajo13888-kwd-0002">pregnancy</kwd><kwd id="ajo13888-kwd-0003">pregnancy complications</kwd><kwd id="ajo13888-kwd-0004">prenatal care</kwd><kwd id="ajo13888-kwd-0005">sickle cell</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><page-count count="7"/><word-count count="3400"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:23.05.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="ajo13888-ntgp-0001"><fn id="ajo13888-note-0001"><p>
<italic toggle="yes">Conflict of Interest</italic>: The authors report no conflicts of interest.</p></fn></fn-group></notes></front><body id="ajo13888-body-0001"><sec id="ajo13888-sec-0001"><title>INTRODUCTION</title><p>Sickle cell disease (SCD) is an autosomal recessive, inherited disorder of haemoglobin (Hb). While still considered a relatively rare disease in Australia, prevalence is increasing as are pregnancies in women with SCD. Pregnancy in women with SCD is associated with a significantly increased risk of maternal and fetal mortality and morbidity.</p><p>It is estimated that approximately 300&#x02009;000 babies are born each year with SCD worldwide, with the majority being in low&#x02010; to middle&#x02010;income countries.<xref rid="ajo13888-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Currently 359 persons with a sickling disorder are recorded in the Australian Haemoglobinopathy Registry. However, it is likely the data are an underestimation due to under&#x02010;reporting and incomplete participation in the registry.<xref rid="ajo13888-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> The prevalence of SCD in Australia is predicted to increase due to migration and improved life expectancy in high&#x02010;income countries.<xref rid="ajo13888-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Therefore, it is expected there will be increasing numbers of pregnant women with SCD seeking medical care in Australia.</p><p>Sickle haemoglobin (HbS) results from a point mutation in the beta globin gene, which leads to a single amino acid substitution (Glu6Val) in the beta globin subunit. This amino acid change results in the propensity for HbS to polymerise in the deoxygenated state and consequent sickling of red blood cells.<xref rid="ajo13888-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> The sickled red cells are inflexible and lead to red cell haemolysis, vaso&#x02010;occlusion, inflammation, hypercoagulability through endothelium activation, ischaemia and subsequent end organ damage. Acute vaso&#x02010;occlusive events lead to episodes of acute pain and tissue damage (pain crisis). Repeated vaso&#x02010;occlusive crises (VOC) lead to permanent damage in all organ systems. eg stroke, chronic kidney disease, pulmonary hypertension and avascular necrosis.<xref rid="ajo13888-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>While sickle cell anaemia refers to homozogosity for HbS, SCD may arise from either HbS homozygosity or compound heterozygosity for HbS together with either a beta thalassaemia mutation or another beta globin variant. The spectrum of implicated partner haemoglobinopathies include beta thalassaemia (Hb&#x000df;<sup>0/+</sup>), HbE, HbO<sup>Arab</sup>, HbD, Hb Lepore and HbC (Fig.&#x000a0;<xref rid="ajo13888-fig-0001" ref-type="fig">1</xref>). Correct molecular characterisation of the partner gene is imperative as it has significant phenotypic implications.</p><fig position="float" fig-type="Figure" id="ajo13888-fig-0001"><label>Figure 1</label><caption><p>Significant haemoglobinopathy genotypes associated with sickle cell disease (adapted from (7)).</p></caption><graphic xlink:href="AJO-65-183-g001" position="anchor" id="jats-graphic-1"/></fig><p>Pregnancy in women with SCD is associated with an increased risk of both maternal and fetal morbidity (Table&#x000a0;<xref rid="ajo13888-tbl-0001" ref-type="table">1</xref>). The physiological changes of pregnancy (prothrombotic state, increased metabolic demand and reduced immunity) increase vulnerability to complications. Women with pre&#x02010;existing medical problems, including those from SCD, are at additional risk. VOC disease may result in placental disorders including placental insufficiency with increased risk of miscarriage, abruption, pre&#x02010;eclampsia, eclampsia, fetal growth restriction, preterm birth, fetal death <italic toggle="yes">in utero</italic>.<xref rid="ajo13888-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="ajo13888-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><table-wrap position="float" id="ajo13888-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Potential complications in sickle cell disease (SCD) during pregnancy</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Risks</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Effect of SCD on maternal health prior to pregnancy</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0001"><list-item id="ajo13888-li-0001"><p>End organ damage, eg cardiomyopathy, chronic kidney disease, pulmonary hypertension, avascular necrosis of hip</p></list-item><list-item id="ajo13888-li-0002"><p>Iron overload</p></list-item><list-item id="ajo13888-li-0003"><p>Chronic pain</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Effect of SCD on pregnant mother</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0002"><list-item id="ajo13888-li-0004"><p>Increased risk of vaso&#x02010;occlusive crises</p></list-item><list-item id="ajo13888-li-0005"><p>Increased risk of thrombosis</p></list-item><list-item id="ajo13888-li-0006"><p>Worsening anaemia</p></list-item><list-item id="ajo13888-li-0007"><p>Increased risk of infection</p></list-item><list-item id="ajo13888-li-0008"><p>Increased risk of placental insufficiency&#x02010;related problems &#x02013; miscarriage, abruption, pre&#x02010;eclampsia, fetal effects (see below)</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Effect of SCD on fetus</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0003"><list-item id="ajo13888-li-0009"><p>Fetal growth restriction</p></list-item><list-item id="ajo13888-li-0010"><p>Preterm birth</p></list-item><list-item id="ajo13888-li-0011"><p>Fetal death <italic toggle="yes">in utero</italic>
</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Effect of medications on fetus</td><td align="left" rowspan="1" colspan="1">Refer to Table&#x000a0;<xref rid="ajo13888-tbl-0002" ref-type="table">2</xref>
</td></tr></tbody></table></table-wrap><p>This position statement provides guidelines for current best practice in the management of SCD during pregnancy in the Australian context, as optimisation of management in pregnancy will result in better outcomes for mother and baby. The primary audience is haematologists, obstetricians, maternal&#x02010;fetal medicine specialists, clinical nurse consultants, clinical nurse educators and associated allied health practitioners, with additional clinicians, such as general practitioners, emergency physicians, general physicians, associated subspecialists and rural practitioners who may provide care in collaborations with the primary treating team. This position statement has been endorsed by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG), Society of Obstetric Medicine of Australia and New Zealand (SOMANZ), Haematology in Obstetrics and Women's Health Collaborative (HOW Collaborative), and the Haematology Society of Australia and New Zealand (HSANZ).</p></sec><sec sec-type="materials-and-methods" id="ajo13888-sec-0002"><title>MATERIALS AND METHODS</title><p>International consensus guidelines and expert position statements<xref rid="ajo13888-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="ajo13888-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ajo13888-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="ajo13888-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="ajo13888-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="ajo13888-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> were reviewed. Application to practice in the Australian healthcare context was considered, with reference to local guidelines and standards. The recommendations were discussed and endorsed by a national panel of expert SCD clinicians.</p></sec><sec id="ajo13888-sec-0003"><title>AUSTRALIAN CONTEXT/APPLICATION</title><p>Australia is a high&#x02010;income country with good access to medications, advanced procedures such as automated red cell exchange transfusion and advanced obstetric medical services. The Australian healthcare funding structure is complex, with funding from national as well as state/territory governments, and non&#x02010;government sources such as private health insurers. Access to safe blood products is coordinated by a national organisation, Australian Red Cross Lifeblood. The blood donor pool is largely Caucasian, which makes it challenging to find phenotype&#x02010;matched blood in phenotypes more common in other ethnic groups, which are overrepresented in the SCD patient cohort.</p><p>SCD is considered a rare disease in the Australian community. Most health professionals, including obstetricians and haematologists, will have limited experience in managing SCD patients. Therefore, it is recommended that SCD pregnancies be managed in centres with experience in SCD and high&#x02010;risk pregnancies.</p></sec><sec id="ajo13888-sec-0004"><title>RECOMMENDATIONS</title><sec id="ajo13888-sec-0005"><title>Pre&#x02010;conception</title><p>Pregnancy outcomes for mother and baby are improved when a woman is in optimal health going into pregnancy. A reproductive health plan should be reviewed bi&#x02010;annually with a pre&#x02010;conception consultation implemented to optimise the mother's health.
<list list-type="order" id="ajo13888-list-0004"><list-item id="ajo13888-li-0012"><p>Screening and genetic testing.
<list list-type="alpha-lower" id="ajo13888-list-0005"><list-item id="ajo13888-li-0013"><p>Establish genotype/phenotype of the woman and partner prior to pregnancy to identify at&#x02010;risk combinations (Fig.&#x000a0;<xref rid="ajo13888-fig-0001" ref-type="fig">1</xref>), which may include full blood count, iron studies, haemoglobinopathy testing and molecular assessment of the alpha and beta globin genes.</p></list-item><list-item id="ajo13888-li-0014"><p>If identified as an at&#x02010;risk couple, refer for genetic counselling and molecular testing. Discuss reproductive options, including non&#x02010;intervention, invasive prenatal diagnosis or <italic toggle="yes">in vitro</italic> fertilisation (IVF) and pre&#x02010;implantation genetic diagnosis. Because options involving molecular testing take time, early referral is recommended.</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0015"><p>Counsel woman that there is an increased risk of complications for both mother and baby during pregnancy (Table&#x000a0;<xref rid="ajo13888-tbl-0001" ref-type="table">1</xref>).</p></list-item><list-item id="ajo13888-li-0016"><p>Counsel woman that there is potentially a reduced fertility window due to accelerated age&#x02010;associated decline in ovarian reserve and consider early referral to reproductive services.</p></list-item></list>
</p><p>
<list list-type="simple" id="ajo13888-list-0006"><list-item id="ajo13888-li-0017"><label>4</label><p>Pre&#x02010;conception comprehensive review overseen by a specialist multidisciplinary coordinated team (MDT) with experience managing these women (Table&#x000a0;<xref rid="ajo13888-tbl-0002" ref-type="table">2</xref>).
<list list-type="alpha-lower" id="ajo13888-list-0007"><list-item id="ajo13888-li-0018"><p>Optimise organ function.</p></list-item><list-item id="ajo13888-li-0019"><p>Review medications and vaccination status.
<list list-type="roman-lower" id="ajo13888-list-0008"><list-item id="ajo13888-li-0020"><p>
<italic toggle="yes">Note on hydroxyurea therapy</italic>: Decisions to continue or cease hydroxyurea should be made in consultation with the MDT experienced in the management of SCD, balancing the benefits of treatment of SCD for mother and fetus with the theoretical risks of exposure of the fetus to hydroxyurea. There is limited but reassuring data about use of hydroxyurea in pregnancy, including during the period of organogenesis, with no significant signal of congenital malformation/teratogenicity.<xref rid="ajo13888-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="ajo13888-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="ajo13888-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> It is important to individualise counselling and advice based on individual maternal health needs and disease phenotype.</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0021"><p>Pre&#x02010;transfusion work up &#x02013; blood group genotype and antibody screen.</p></list-item><list-item id="ajo13888-li-0022"><p>Folic acid 5&#x02009;mg daily.</p></list-item><list-item id="ajo13888-li-0023"><p>Review and update the reproductive health plan.</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0024"><label>5</label><p>Consider referral to appropriate subspecialty for additional pre&#x02010;pregnancy counselling: pregnancy unit with experience in the management of SCD, fertility, maternal&#x02010;fetal medicine (MFM), pharmacy, cardiology, nephrology and endocrinology.</p></list-item></list>
</p><table-wrap position="float" id="ajo13888-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Comprehensive review and sickle cell disease (SCD) specific management for pregnancy care (note: standard obstetric investigations should also be completed as part of routine care)</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Review/assess</th><th align="center" rowspan="1" colspan="1">Action</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">End organ function</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<p>Cardiac function</p>
<p>Pulmonary hypertension</p>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0009"><list-item id="ajo13888-li-0025"><p>Echocardiography</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Chronic lung disease</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0010"><list-item id="ajo13888-li-0026"><p>Pulse oximetry</p></list-item><list-item id="ajo13888-li-0027"><p>Pulmonary function test</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Renal function</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0011"><list-item id="ajo13888-li-0028"><p>Blood pressure</p></list-item><list-item id="ajo13888-li-0029"><p>Serum creatinine</p></list-item><list-item id="ajo13888-li-0030"><p>Urinary protein creatinine ratio, albumin creatinine ratio</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Avascular necrosis (AVN) (hips)</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0012"><list-item id="ajo13888-li-0031"><p>Review history of AVN, may affect mode of birth</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke and silent cerebral ischaemia</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0013"><list-item id="ajo13888-li-0032"><p>Transfusion program for primary or secondary prevention if history of stroke</p></list-item></list>
</td></tr><tr><td align="left" colspan="2" rowspan="1">Blood tests</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Iron status</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0014"><list-item id="ajo13888-li-0033"><p>Iron studies</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Full blood count</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0015"><list-item id="ajo13888-li-0034"><p>Baseline Hb</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Haemoglobinopathy tests</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0016"><list-item id="ajo13888-li-0035"><p>Baseline HbS, HbF</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">
<p>Blood group and antibody screen</p>
<p>Red cell genotype (or phenotype if genotype not available)</p>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0017"><list-item id="ajo13888-li-0036"><p>Liaise with blood bank regarding transfusion plans during pregnancy and birth</p></list-item><list-item id="ajo13888-li-0037"><p>Partner red cell phenotype if maternal red cell antibodies</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Red cell product requirements</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0018"><list-item id="ajo13888-li-0038"><p>ABO&#x02010;compatible</p></list-item><list-item id="ajo13888-li-0039"><p>RhD,C,c,E,e, Kell&#x02010;matched</p></list-item><list-item id="ajo13888-li-0040"><p>Antigen negative if allo&#x02010;immunised</p></list-item><list-item id="ajo13888-li-0041"><p>Consider extended matching if feasible</p></list-item><list-item id="ajo13888-li-0042"><p>Cytomegalovirus&#x02010;negative</p></list-item></list>
</td></tr><tr><td align="left" colspan="2" rowspan="1">
<p>Functional asplenia</p>
<p>Encourage registration with Spleen Australia (<ext-link xlink:href="http://spleen.org.au" ext-link-type="uri">spleen.org.au</ext-link>)</p>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Vaccines</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0019"><list-item id="ajo13888-li-0043"><p>Asplenic vaccinations (meningococcal, pneumococcal)</p></list-item><list-item id="ajo13888-li-0044"><p>Influenza vaccination</p></list-item><list-item id="ajo13888-li-0045"><p>Covid vaccination</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotics</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0020"><list-item id="ajo13888-li-0046"><p>Prophylactic penicillin vs emergency supply/sick day plan</p></list-item></list>
</td></tr><tr><td align="left" colspan="2" rowspan="1">Medication review</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Acute/chronic pain medications</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0021"><list-item id="ajo13888-li-0047"><p>Update acute pain plan for pregnancy</p></list-item><list-item id="ajo13888-li-0048"><p>Paracetamol is safe in pregnancy</p></list-item><list-item id="ajo13888-li-0049"><p>Nonsteroidal anti&#x02010;inflammatories can be used between 12 and 20&#x02009;weeks. Avoid after 20&#x02009;weeks due to oligohydramnios risk<xref rid="ajo13888-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p></list-item><list-item id="ajo13888-li-0050"><p>Chronic pain team involvement for chronic opioid therapy</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hydroxyurea</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0022"><list-item id="ajo13888-li-0051"><p>If safe to discontinue during pregnancy, stop hydroxyurea when pregnancy confirmed. Consider commencement of red cell exchange or top&#x02010;up transfusion and consider restarting hydroxyurea after the first trimester.</p></list-item><list-item id="ajo13888-li-0052"><p>Continuing hydroxyurea therapy may be appropriate in some cases (see Pre&#x02010;conception Recommendation 3.b.i. for details).</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Emerging therapies (not currently available in Australia)</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0023"><list-item id="ajo13888-li-0053"><p>Currently no safety data in pregnancy for the use of voxelotor, protein kinase inhibitors. Cease before attempting to conceive</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Iron chelation</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0024"><list-item id="ajo13888-li-0054"><p>Stop when pregnancy confirmed</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB)</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0025"><list-item id="ajo13888-li-0055"><p>Switch to alternative antihypertensive prior to planned pregnancy. Stop ACEIs and ARBs when pregnancy confirmed and must be ceased by end of first trimester</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vitamins</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0026"><list-item id="ajo13888-li-0056"><p>Folic acid 5&#x02009;mg daily</p></list-item><list-item id="ajo13888-li-0057"><p>Routine pregnancy multivitamin. If iron overload present, administer multivitamin without iron</p></list-item><list-item id="ajo13888-li-0058"><p>Vitamin D supplement if deficient</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0027"><list-item id="ajo13888-li-0059"><p>Pre&#x02010;eclampsia prophylaxis</p></list-item><list-item id="ajo13888-li-0060"><p>150&#x02009;mg daily when pregnancy confirmed to 36&#x02009;weeks gestation</p></list-item></list>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Venous thromboembolism (VTE) thromboprophylaxis</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0028"><list-item id="ajo13888-li-0061"><p>For example, enoxaparin 40&#x02009;mg subcutaneous daily</p></list-item><list-item id="ajo13888-li-0062"><p>During all admissions unless contraindicated</p></list-item><list-item id="ajo13888-li-0063"><p>Antepartum &#x02013; consider VTE thromboprophylaxis on a case&#x02010;by&#x02010;case basis based on risk profile</p></list-item><list-item id="ajo13888-li-0064"><p>Post&#x02010;partum VTE thromboprophylaxis is recommended for six weeks</p></list-item></list>
</td></tr></tbody></table></table-wrap></sec><sec id="ajo13888-sec-0006"><title>Management in pregnancy</title><sec id="ajo13888-sec-0007"><title>General</title><p>
<list list-type="order" id="ajo13888-list-0029"><list-item id="ajo13888-li-0065"><p>Management by a specialist multidisciplinary coordinated team with experience managing pregnancy in SCD. Early referral recommended.</p></list-item><list-item id="ajo13888-li-0066"><p>Assess and optimise as per Table&#x000a0;<xref rid="ajo13888-tbl-0002" ref-type="table">2</xref> if not completed.</p></list-item><list-item id="ajo13888-li-0067"><p>Confirm/establish haemoglobinopathy genotype of mother and partner within the first trimester, (see Pre&#x02010;conception Recommendations).</p></list-item><list-item id="ajo13888-li-0068"><p>Monitoring as per Table&#x000a0;<xref rid="ajo13888-tbl-0003" ref-type="table">3</xref>.</p></list-item><list-item id="ajo13888-li-0069"><p>Prompt treatment of crisis triggers &#x02013; eg persistent vomiting and dehydration, associated with nausea and vomiting of pregnancy and hyperemesis gravidarum, infection.</p></list-item><list-item id="ajo13888-li-0070"><p>Aspirin 150&#x02009;mg daily from pregnancy confirmation to 36&#x02009;weeks gestation.</p></list-item><list-item id="ajo13888-li-0071"><p>Low threshold for admission.</p></list-item><list-item id="ajo13888-li-0072"><p>Develop a written intra&#x02010;partum and post&#x02010;partum management plan in consultation with the mother, haematologist, MFM specialist, neonatologist and MDT team.</p></list-item></list>
</p><table-wrap position="float" id="ajo13888-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Monitoring during pregnancy in sickle cell disease in addition to routine pregnancy care</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><tbody><tr><td align="left" rowspan="1" colspan="1">Obstetric monitoring</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0030"><list-item id="ajo13888-li-0073"><p>Involve mother&#x02010;fetal medicine/high risk obstetric service</p></list-item><list-item id="ajo13888-li-0074"><p>Visits may be required more frequently</p></list-item><list-item id="ajo13888-li-0075"><p>Screen for
<list list-type="bullet" id="ajo13888-list-0031"><list-item id="ajo13888-li-0076"><p>Pre&#x02010;eclampsia</p></list-item><list-item id="ajo13888-li-0077"><p>Urinary infection (early pregnancy)</p></list-item><list-item id="ajo13888-li-0078"><p>Anaemia</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0079"><p>Be alert for
<list list-type="bullet" id="ajo13888-list-0032"><list-item id="ajo13888-li-0080"><p>dehydration</p></list-item><list-item id="ajo13888-li-0081"><p>infection</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0082"><p>Pain that is not obstetric</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Haematology</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0033"><list-item id="ajo13888-li-0083"><p>Arrange regular visits throughout pregnancy</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Other specialists, eg cardiologist, anaesthetist</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0034"><list-item id="ajo13888-li-0084"><p>As needed</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Fetal monitoring</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0035"><list-item id="ajo13888-li-0085"><p>Dating scan in early pregnancy</p></list-item><list-item id="ajo13888-li-0086"><p>Screen for fetal growth restriction, eg monthly</p></list-item><list-item id="ajo13888-li-0087"><p>Serial growth scans from 24&#x02009;weeks</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Multidisciplinary agreement and documented plans</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ajo13888-list-0036"><list-item id="ajo13888-li-0088"><p>Plans for admissions, labour, birth and post&#x02010;partum care</p></list-item></list>
</td></tr></tbody></table></table-wrap></sec><sec id="ajo13888-sec-0008"><title>Blood transfusions during pregnancy</title><p>
<list list-type="order" id="ajo13888-list-0037"><list-item id="ajo13888-li-0089"><p>Ensure blood group, antibody screen and red cell genotype (phenotype if genotype not available and patient has not been transfused in last three&#x02009;months) has been performed.</p></list-item><list-item id="ajo13888-li-0090"><p>If transfusion is needed, pregnant women with SCD should be given ABO&#x02010;compatible, extended Rh (ie RhD, C, c, E, e) and Kell&#x02010;matched, cytomegalovirus&#x02010;negative units. Consider matching for Duffy as possible. If there are clinically significant red cell antibodies (current or historical) then the red cells selected should be negative for the corresponding antigens.</p></list-item></list>
</p><p>Pregnancy is not an indication for prophylactic blood transfusion. Women on transfusion therapy prior to conception should continue their routine therapy. Women who transition off hydroxyurea for or during pregnancy may require commencement of transfusion therapy to prevent SCD complications, including VOC. There is a preference for red cell exchange transfusion; however, top&#x02010;up transfusions are also acceptable.</p></sec><sec id="ajo13888-sec-0009"><title>Management of complications</title><sec id="ajo13888-sec-0010"><title>Principles of management</title><p>
<list list-type="order" id="ajo13888-list-0038"><list-item id="ajo13888-li-0091"><p>Low threshold for admission.</p></list-item><list-item id="ajo13888-li-0092"><p>Joint management by haematology, obstetrics, obstetric medicine &#x02013; admitting team/ward determined by required skill set for stage of pregnancy and issue at hand.</p></list-item><list-item id="ajo13888-li-0093"><p>Consider sickle&#x02010;related, obstetric and other non&#x02010;obstetric causes for presenting symptoms.</p></list-item></list>
</p></sec><sec id="ajo13888-sec-0011"><title>Management of acute VOC</title><p>
<list list-type="order" id="ajo13888-list-0039"><list-item id="ajo13888-li-0094"><p>Thorough assessment to determine if pain is due to VOC (eg typical pain crisis symptoms for that woman) or other cause in the obstetric setting.</p></list-item><list-item id="ajo13888-li-0095"><p>Consult patient's agreed pain management plan if available.</p></list-item><list-item id="ajo13888-li-0096"><p>Follow standard pain management guidelines and involvement of acute pain service.</p></list-item><list-item id="ajo13888-li-0097"><p>Avoid nonsteroidal anti&#x02010;inflammatories in first and third trimesters, use judiciously between 12 and 20&#x02009;weeks.</p></list-item><list-item id="ajo13888-li-0098"><p>Low threshold for admission and venous thromboembolism (VTE) thromboprophylaxis.</p></list-item><list-item id="ajo13888-li-0099"><p>Monitor fluid and oxygen balance carefully.</p></list-item><list-item id="ajo13888-li-0100"><p>Have high level of vigilance for acute chest syndrome.</p></list-item></list>
</p></sec><sec id="ajo13888-sec-0012"><title>Management of VTE and thromboprophylaxis</title><p>
<list list-type="order" id="ajo13888-list-0040"><list-item id="ajo13888-li-0101"><p>VTE risk is increased throughout pregnancy and the post&#x02010;partum period.</p></list-item><list-item id="ajo13888-li-0102"><p>Consider VTE thromboprophylaxis on a case&#x02010;by&#x02010;case basis.</p></list-item><list-item id="ajo13888-li-0103"><p>Administer low molecular weight heparin for VTE thromboprophylaxis, as per usual guidelines.</p></list-item><list-item id="ajo13888-li-0104"><p>Consideration of risks and benefits of anticoagulation, especially in the third trimester considering the risk of VTE vs risks such as placental abruption and unplanned early birth.</p></list-item><list-item id="ajo13888-li-0105"><p>Management of VTE as per standard VTE guidelines in pregnancy.</p></list-item></list>
</p></sec></sec></sec><sec id="ajo13888-sec-0013"><title>Pre&#x02010;delivery plan</title><p>
<list list-type="bullet" id="ajo13888-list-0041"><list-item id="ajo13888-li-0106"><p>Ensure all members of MDT are aware of peripartum plan</p></list-item><list-item id="ajo13888-li-0107"><p>Anaesthetic review</p></list-item><list-item id="ajo13888-li-0108"><p>Anticoagulation plan</p></list-item><list-item id="ajo13888-li-0109"><p>Pain management</p></list-item><list-item id="ajo13888-li-0110"><p>Blood bank notification</p></list-item></list>
</p></sec><sec id="ajo13888-sec-0014"><title>Intrapartum care (vaginal birth and caesarean section)</title><p>
<list list-type="order" id="ajo13888-list-0042"><list-item id="ajo13888-li-0111"><p>Late third trimester, intrapartum and post&#x02010;partum are periods of increased risk for complications.</p></list-item><list-item id="ajo13888-li-0112"><p>Birth should occur in hospitals that are able to manage both the complications of SCD and high&#x02010;risk pregnancies in an MDT setting, with involvement of experienced clinicians.</p></list-item><list-item id="ajo13888-li-0113"><p>Timing of birth should be directed by usual obstetric indications. There is no evidence to recommend a given gestation; however, birth by term should be considered due to the risk of late pregnancy complications.</p></list-item><list-item id="ajo13888-li-0114"><p>Mode of birth should be directed by usual obstetric indications.</p></list-item><list-item id="ajo13888-li-0115"><p>Consideration of positioning during labour/birth for women with hip/joint necrosis.</p></list-item><list-item id="ajo13888-li-0116"><p>Communicate with blood bank to have extended matched red cell units available on admission.</p></list-item><list-item id="ajo13888-li-0117"><p>Epidural is not contraindicated and may offer advantages during labour in SCD.</p></list-item><list-item id="ajo13888-li-0118"><p>Avoid crisis precipitants in labour:
<list list-type="alpha-lower" id="ajo13888-list-0043"><list-item id="ajo13888-li-0119"><p>maintain hydration</p></list-item><list-item id="ajo13888-li-0120"><p>keep warm</p></list-item><list-item id="ajo13888-li-0121"><p>monitor vital signs and maintain oxygen saturations &#x02265;97%</p></list-item><list-item id="ajo13888-li-0122"><p>regular assessment of progress to avoid protracted labour</p></list-item><list-item id="ajo13888-li-0123"><p>encourage incentive spirometry/deep breathing exercises.</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0124"><p>Continuous fetal monitoring is directed by the usual indications.</p></list-item><list-item id="ajo13888-li-0125"><p>Regional anaesthesia is preferred over general anaesthesia.</p></list-item><list-item id="ajo13888-li-0126"><p>Consider an elective pre&#x02010;delivery red cell exchange in patients considered high risk of crisis.</p></list-item></list>
</p></sec><sec id="ajo13888-sec-0015"><title>Post&#x02010;partum care, optimal post&#x02010;birth care</title><sec id="ajo13888-sec-0016"><title>Mother</title><p>
<list list-type="order" id="ajo13888-list-0044"><list-item id="ajo13888-li-0127"><p>The postnatal period is a time of increased risk of pain. Precipitants should be anticipated and avoided:
<list list-type="alpha-lower" id="ajo13888-list-0045"><list-item id="ajo13888-li-0128"><p>maintain consistent analgesia, hydration and oxygenation, with early mobilisation</p></list-item><list-item id="ajo13888-li-0129"><p>support adequate rest to minimise sleep deprivation.</p></list-item></list>
</p></list-item><list-item id="ajo13888-li-0130"><p>Breastfeeding is not contraindicated. Use specialised services to assess exposures in breastfeeding, such as MotherSafe and LactMed.</p></list-item><list-item id="ajo13888-li-0131"><p>Schedule recommencement of regular pre&#x02010;pregnancy medications.</p></list-item><list-item id="ajo13888-li-0132"><p>VTE thromboprophylaxis for six weeks after birth.</p></list-item><list-item id="ajo13888-li-0133"><p>Contraception should be individualised and discussed prior to discharge.</p></list-item></list>
</p></sec><sec id="ajo13888-sec-0017"><title>Baby</title><p>
<list list-type="order" id="ajo13888-list-0046"><list-item id="ajo13888-li-0134"><p>Screen for SCD in infant, if at risk.</p></list-item><list-item id="ajo13888-li-0135"><p>Monitor for neonatal abstinence syndrome, haemolytic disease of the newborn if applicable.</p></list-item></list>
</p></sec></sec></sec><sec id="ajo13888-sec-0018"><title>LIMITATIONS/OTHER CONSIDERATIONS</title><p>Due to limited literature available on this topic, this consensus statement is based on low&#x02010;level evidence and expert opinion. While these recommendations are considered best practice in the Australian setting, practice between centres may vary depending on availability of resources.</p><p>Reproductive issues in SCD, including subfertility in women and men are beyond the scope of this consensus statement and are comprehensively addressed elsewhere.<xref rid="ajo13888-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="ajo13888-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</p></sec><sec sec-type="conclusions" id="ajo13888-sec-0019"><title>CONCLUSION</title><p>Early and comprehensive multidisciplinary care involving experienced clinicians, nurses, midwifes and other allied healthcare professionals, is pivotal in achieving optimal outcomes for women with SCD and their infants in both the antenatal and perinatal setting.</p></sec><sec id="ajo13888-sec-0021"><title>FINANCIAL AND MATERIAL SUPPORT</title><p>No financial support was received.</p></sec></body><back><ack id="ajo13888-sec-0020"><title>ACKNOWLEDGEMENTS</title><p>We are grateful to Dr Anthea Greenaway, Prof Joy Ho, Dr Agnes Yong, Dr Pasquale Barbaro, Dr Anastazia Keegan, A/Prof Jennifer Curnow and Dr Briony Cutts for their thoughtful comments on the manuscript. Open access publishing facilitated by University of New South Wales, as part of the Wiley &#x02010; University of New South Wales agreement via the Council of Australian University Librarians.</p></ack><ref-list content-type="cited-references" id="ajo13888-bibl-0001"><title>REFERENCES</title><ref id="ajo13888-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ajo13888-cit-0001">
<string-name>
<surname>Piel</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Hay</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Global burden of sickle cell anaemia in children under five, 2010&#x02013;2050: Modelling based on demographics, excess mortality, and interventions</article-title>. <source>PLoS Med</source>
<year>2013</year>; <volume>10</volume>(<issue>7</issue>): <elocation-id>e1001484</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1001484</pub-id>.<pub-id pub-id-type="pmid">23874164</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ajo13888-cit-0002">
<string-name>
<surname>Nelson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Haysom</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Sickle cell disease in Australia: A snapshot from the Australian Haemoglobinopathy registry</article-title>. <source>Intern Med J</source>
<year>2023</year>; <volume>54</volume>: <fpage>764</fpage>&#x02013;<lpage>772</lpage>. <pub-id pub-id-type="doi">10.1111/imj.16297</pub-id>.<pub-id pub-id-type="pmid">38064543</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ajo13888-cit-0003">
<string-name>
<surname>Hassell</surname>
<given-names>KL</given-names>
</string-name>. <article-title>Population estimates of sickle cell disease in the U.S</article-title>. <source>Am J Prev Med</source>
<year>2010</year>; <volume>38</volume>(<issue>4 Suppl</issue>): <fpage>S512</fpage>&#x02013;<lpage>S521</lpage>. <pub-id pub-id-type="doi">10.1016/j.amepre.2009.12.022</pub-id>.<pub-id pub-id-type="pmid">20331952</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ajo13888-cit-0004">
<string-name>
<surname>Kato</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Piel</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Reid</surname>
<given-names>CD</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Sickle cell disease</article-title>. <source>Nat Rev Dis Primers</source>
<year>2018</year>; <volume>4</volume>: <elocation-id>18010</elocation-id>
<pub-id pub-id-type="doi">10.1038/nrdp.2018.10</pub-id>.<pub-id pub-id-type="pmid">29542687</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ajo13888-cit-0005">
<string-name>
<surname>Piel</surname>
<given-names>FB</given-names>
</string-name>, <string-name>
<surname>Steinberg</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Rees</surname>
<given-names>DC</given-names>
</string-name>. <article-title>Sickle cell disease</article-title>. <source>N Engl J Med</source>
<year>2017</year>; <volume>376</volume>(<issue>16</issue>): <fpage>1561</fpage>&#x02013;<lpage>1573</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1510865</pub-id>.<pub-id pub-id-type="pmid">28423290</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ajo13888-cit-0006">
<string-name>
<surname>Smith&#x02010;Whitley</surname>
<given-names>K</given-names>
</string-name>. <article-title>Complications in pregnant women with sickle cell disease</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>
<year>2019</year>; <volume>2019</volume>(<issue>1</issue>): <fpage>359</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1182/hematology.2019000039</pub-id>.<pub-id pub-id-type="pmid">31808864</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ajo13888-cit-0007">
<string-name>
<surname>Oteng&#x02010;Ntim</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pavord</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>R</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Management of sickle cell disease in pregnancy. A British Society for Haematology guideline</article-title>. <source>Br J Haematol</source>
<year>2021</year>; <volume>194</volume>(<issue>6</issue>): <fpage>980</fpage>&#x02013;<lpage>995</lpage>. <pub-id pub-id-type="doi">10.1111/bjh.17671</pub-id>.<pub-id pub-id-type="pmid">34409598</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0008"><label>8</label><mixed-citation publication-type="book" id="ajo13888-cit-0008">
<collab collab-type="authors">Sickle Cell Society</collab>
. <source>Standards for Clinical Care of Adults with Sickle Cell Disease in the UK</source>, <edition designator="2">2nd edn</edition>. <publisher-loc>UK</publisher-loc>: <publisher-name>Sickle Cell Society</publisher-name>, <year>2018</year>; <ext-link xlink:href="http://www.sicklecellsociety.org" ext-link-type="uri">www.sicklecellsociety.org</ext-link>.</mixed-citation></ref><ref id="ajo13888-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="ajo13888-cit-0009">
<collab collab-type="authors">(NICE) NIfHaCE</collab>
. <article-title>Sickle cell disease: managing acute painful episodes in hospital. NICE Clinical Guideline 143</article-title>. [Internet]. 2012. Accessed 11 September 2023. Available from URL: <ext-link xlink:href="http://nice.org.uk/guidance/cg143" ext-link-type="uri">nice.org.uk/guidance/cg143</ext-link>.</mixed-citation></ref><ref id="ajo13888-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ajo13888-cit-0010">
<string-name>
<surname>Chou</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Alsawas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fasano</surname>
<given-names>RM</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>American Society of Hematology 2020 guidelines for sickle cell disease: Transfusion support</article-title>. <source>Blood Adv</source>
<year>2020</year>; <volume>4</volume>(<issue>2</issue>): <fpage>327</fpage>&#x02013;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2019001143</pub-id>.<pub-id pub-id-type="pmid">31985807</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="ajo13888-cit-0011">
<collab collab-type="authors">(NHLBI) NHLaBI</collab>
. <article-title>
<italic toggle="yes">Evidence&#x02010;Based Management of Sickle Cell Disease: Expert Panel</italic>, 2014 [Internet]</article-title>. <year>2014</year>. Accessed 8 July 2022. Available from URL: <ext-link xlink:href="http://www.nhlbi.nih.gov/guidelines" ext-link-type="uri">http://www.nhlbi.nih.gov/guidelines</ext-link>.</mixed-citation></ref><ref id="ajo13888-bib-0012"><label>12</label><mixed-citation publication-type="miscellaneous" id="ajo13888-cit-0012">
<collab collab-type="authors">CanHaem Association</collab>
. <article-title>
<italic toggle="yes">Consensus statement on the Care of Patients with Sickle Cell Disease in Canada</italic> [Internet]. 2nd edn</article-title>. Accessed 8 July 2022. Available from URL: <ext-link xlink:href="https://www.canhaem.org/wp-content/uploads/2018/05/Sickle-Cell-Consensus.pdf" ext-link-type="uri">https://www.canhaem.org/wp&#x02010;content/uploads/2018/05/Sickle&#x02010;Cell&#x02010;Consensus.pdf</ext-link>.</mixed-citation></ref><ref id="ajo13888-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="ajo13888-cit-0013">
<string-name>
<surname>Kroner</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Hankins</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Pugh</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Pregnancy outcomes with hydroxyurea use in women with sickle cell disease</article-title>. <source>Am J Hematol</source>
<year>2022</year>; <volume>97</volume>(<issue>5</issue>): <fpage>603</fpage>&#x02013;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1002/ajh.26495</pub-id>.<pub-id pub-id-type="pmid">35142007</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ajo13888-cit-0014">
<string-name>
<surname>Gellen&#x02010;Dautremer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Le Jeune</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Receveur</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Fois</surname>
<given-names>E</given-names>
</string-name>. <article-title>Hydroxyurea exposure throughout pregnancy in patients with sickle&#x02010;cell disease: 4 case reports from European non&#x02010;interventional, multicentric, prospective escort&#x02010;HU study</article-title>. <source>Blood</source>
<year>2019</year>; <volume>134</volume>(<issue>Supplement 1</issue>): <fpage>1027</fpage> (Conference Abstract).</mixed-citation></ref><ref id="ajo13888-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ajo13888-cit-0015">
<string-name>
<surname>Ballas</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>McCarthy</surname>
<given-names>WF</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia</article-title>. <source>J Natl Med Assoc</source>
<year>2009</year>; <volume>101</volume>(<issue>10</issue>): <fpage>1046</fpage>&#x02013;<lpage>1051</lpage>. <pub-id pub-id-type="doi">10.1016/s0027-9684(15)31072-5</pub-id>.<pub-id pub-id-type="pmid">19860305</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ajo13888-cit-0016">
<string-name>
<surname>Dathe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Frank</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Padberg</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et al</italic>. <article-title>Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: An evaluation of the German Embryotox cohort</article-title>. <source>BMC Pregnancy Childbirth</source>
<year>2022</year>; <volume>22</volume>(<issue>1</issue>): <fpage>666</fpage>
<pub-id pub-id-type="doi">10.1186/s12884-022-04986-4</pub-id>.<pub-id pub-id-type="pmid">36028798</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ajo13888-cit-0017">
<string-name>
<surname>Pecker</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Nero</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Christianson</surname>
<given-names>M</given-names>
</string-name>. <article-title>No crystal stair: Supporting fertility care and the pursuit of pregnancy in women with sickle cell disease</article-title>. <source>Hematology Am Soc Hematol Educ Program</source>
<year>2022</year>; <volume>2022</volume>(<issue>1</issue>): <fpage>459</fpage>&#x02013;<lpage>466</lpage>. <pub-id pub-id-type="doi">10.1182/hematology.2022000381</pub-id>.<pub-id pub-id-type="pmid">36485154</pub-id>
</mixed-citation></ref><ref id="ajo13888-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ajo13888-cit-0018">
<string-name>
<surname>Huang</surname>
<given-names>AW</given-names>
</string-name>, <string-name>
<surname>Muneyyirci&#x02010;Delale</surname>
<given-names>O</given-names>
</string-name>. <article-title>Reproductive endocrine issues in men with sickle cell anemia</article-title>. <source>Andrology</source>
<year>2017</year>; <volume>5</volume>(<issue>4</issue>): <fpage>679</fpage>&#x02013;<lpage>690</lpage>. <pub-id pub-id-type="doi">10.1111/andr.12370</pub-id>.<pub-id pub-id-type="pmid">28662541</pub-id>
</mixed-citation></ref></ref-list></back></article>